finance

Sperm motility illustration
Biotech

‘The gurus of sperm’: Ohana Biosciences is taking a different approach to fertility 

By Kate Sheridan

23andMe kits
Business

23andMe laying off 14% of employees amid slump in DNA spit kit sales

By Erin Brodwin

Drug pricing transparency
Pharmalot

Many patient groups have deep ties to pharma but fail to disclose backing

By Ed Silverman

Brain neurons
Biotech

A venture firm warms to funding neuroscience

By Matthew Herper

Patrick Soon-Shiong
Biotech

After a single patient drives a big stock surge, Patrick Soon-Shiong makes his case to investors

By Rebecca Robbins

Pharmalot

Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?

By Elizabeth Cooney

SHATTERED DIGIPILL
Exclusive

A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels

By Rebecca Robbins

JPM 2020 Lombard St
Adam's Take

All talk, no M&A makes for a down JPM Day

By Adam Feuerstein

Adam's Take

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

By Adam Feuerstein

Knee replacement
Biotech

Anika Therapeutics acquires two companies for their joint-replacement products

By Jonathan Saltzman — Boston Globe

ASH19 sickle cell disease blood sample
Biotech

In a shift toward venture capital fundraising, FORMA Therapeutics brings in $100 million 

By Kate Sheridan

Purdue in the weeds
Business

Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying

By Nicholas Florko

Dr. Bar Peled
Health

In novel partnership with cancer group, biotech venture firm doles out grants for research

By Kate Sheridan

Something ventured illo
Biotech

Something Ventured: Akrevia Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

STAT New York Event
Biotech

Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict 

By Kate Sheridan

George Church
Biotech

Veritas, genetics company founded by George Church, suspends U.S. operations

By Kate Sheridan

Credit card in hand
First Opinion

Step aside, biomarkers. Look to the bank account for early signs of dementia

By Eric Chess

Pill vapor
Biotech

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

By Kate Sheridan

Pharmalot

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

By Ed Silverman

The State of Biotech
Biotech

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

By Kate Sheridan

D.C. Insight IMAGE
Politics

Biotech venture capitalists form a lobbying coalition to join the drug pricing debate 

By Nicholas Florko

Broad Institute signage
Biotech

Novo Nordisk’s parent company to launch research incubator in Boston

By Kate Sheridan

Nancy Pelosi
Politics

In a rare political move, prominent biotech venture capitalists speak out against Pelosi’s drug pricing bill

By Nicholas Florko

Jorge Conde Andreessen Horowitz
Biotech

When bio-Twitter greets a sincere thread with snark, what can a Silicon Valley VC say?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Post society molecule landscape
Biotech

It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill

By Nicholas Florko

Social network
Biotech

Social connections first, science second: How biotech’s recipe for success has its limits

By Kate Sheridan

Calculator close up
Opinions Plus

Early price setting, other market access planning is key for early-stage drug, device companies

By Christopher Leo, Christian Thienel, and Brendan Wang

David Hung
Biotech

Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

By Kate Sheridan

Steven St. Peter
Biotech

The country’s only diabetes-focused venture fund brings on a new partner

By Kate Sheridan

Your daily dose of news in health and medicine

Privacy Policy